Terns Pharma acquires greater China rights to treat liver disease

A prospectus has been filed for the Hong Kong IPO by the specialty pharma company, Tesla Biopharma. The anticipated transaction could raise around $1Bn. Tasly Bio is the biologics branch of Tasly Pharma, A TCM firm which decided in 2001…